[2-[bis(phosphonomethyl)amino]ethyl-(phosphonomethyl)amino]methylphosphonic acid;samarium-153

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机膦酸及其衍生物
• 英文名称: [2-[bis(phosphonomethyl)amino]ethyl-(phosphonomethyl)amino]methylphosphonic acid;samarium-153
• 化学式: C6H20N2O12P4Sm
• 分子量: 589.05
• InChiKey: WNYXBFNBLZLWRA-GJNDDOAHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.87
• 重原子数：
  25
• 可旋转键数：
  11
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  237
• 氢给体数：
  8
• 氢受体数：
  14

ADMET

毒理性

• 在妊娠和哺乳期间的影响

◉ 母乳喂养期间使用总结：本记录中的信息是指将钐Sm 153 lexidronam pentasodium作为一种治疗剂的使用。目前没有关于在哺乳期间使用钐Sm 153 lexidronam pentasodium的信息。大多数使用钐Sm 153治疗的疾病不会发生在希望哺乳的母亲身上。然而，制造商建议不要给希望继续哺乳的妇女使用该药物。由于钐153的半衰期相对较长，标准的等待期（10个半衰期）将接近3周，这对于恢复哺乳可能是不切实际的。制造商和专家意见建议，如果使用了该药物，应停止哺乳。 担心乳汁中放射活性的母亲可以要求在医院核医学科进行检测。当放射性水平达到背景水平时，她们可以安全地恢复哺乳。已经发布了一种测量乳汁放射性和确定母亲可以安全恢复哺乳时间的方法。 ◉ 对哺乳婴儿的影响：截至修订日期，未找到相关已发布信息。 ◉ 对泌乳和乳汁的影响：截至修订日期，未找到相关已发布信息。

◉ Summary of Use during Lactation:Information in this record refers to the use of samarium Sm 153 lexidronam pentasodium as a therapeutic agent. No information is available on the use of samarium Sm 153 lexidronam pentasodium during breastfeeding. Most conditions treated with samarium Sm 153 would not occur in mothers wishing to nurse. However, the manufacturer recommends not administering the drug in women who wish to continue breastfeeding. Because of the relatively long half-life of samarium 153, the standard waiting period of 10 half-lives would be close to 3 weeks which might be impractical for resuming breastfeeding. The manufacturer and expert opinion recommend discontinuing breastfeeding if the agent is administered. Mothers concerned about the level of radioactivity in their milk could ask to have it tested at a nuclear medicine facility at their hospital. When the radioactivity is at background levels they may safely resume breastfeeding. A method for measuring milk radioactivity and determining the time when a mother can safely resume breastfeeding has been published. ◉ Effects in Breastfed Infants:Relevant published information was not found as of the revision date. ◉ Effects on Lactation and Breastmilk:Relevant published information was not found as of the revision date.

来源:Drugs and Lactation Database (LactMed)

文献信息

• US7790905B2
  申请人：——

  公开号：US7790905B2

  公开（公告）日：2010-09-07
• US7927613B2
  申请人：——

  公开号：US7927613B2

  公开（公告）日：2011-04-19